Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$9.70
-$0.34(-6.35%)
At close: 4:00 PM EST
$9.70
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$2.22 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.48M
Market Cap
$824.35M
Enterprise Value$821.43M
Total Cash (Recent Filing)$152.19M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Feb 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding92,727,530
10 Day Avg. Volume1,301,896
30 Day Avg. Volume1,481,934
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.68K
Enterprise Value/Ebitda-10.13
Forecast
1Y Price Target
$16.00Price Target Upside64.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SuccessManagement expects to see a ≥35% placebo-adjusted change in hypoglycemic events in sunRIZE, with high odds of being met or exceeded, considering previous results showed a 74% reduction in hypoglycemic events.
Market PotentialErsodetug is expected to reach more than 50% of the approximately 3,000 prevalent patient population at peak.
Regulatory AlignmentThe F1Q26 update reaffirmed an alignment between RZLT and the FDA that the Ph3 sunRIZE study of ersodetug in congenital hyperinsulinism (HI) meets registrational requirements for BLA filing and review.
Bears Say
Clinical Study EffectsDr. Thornton cautioned that participation in a clinical study alone may lead to improvement in hypoglycemia control due to more rigorous monitoring creating positive effects.
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Data InterpretationDr. Thornton cautioned that a placebo effect could be possible, emphasizing the importance of careful data interpretation when Ph3 top-line data become available.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $2.21 and its highest was $11.46 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $824.35M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Feb 11, 2026 which is in 67 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Nov 06, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.19.
How many shares outstanding does Rezolute have?
Rezolute has 92,727,530 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went up 12.083%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (64.95% Upside)
$16.00 (64.95% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.98%
12-Months-Change
Fundamentals
Return on Equity
-59.23%
Trailing 12-Months
Asset Growth
28.56%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and orphan diseases. The company is primarily engaged in the research and development of innovative treatments targeting serious conditions such as rare metabolic disorders. Its core product candidates include RZ358, an antibody designed to treat congenital hyperinsulinism, and RZ402, an oral therapy aimed at diabetic macular edema.
RZLT Stock 12 Month Forecast
Average Price Target
$16.00
▲(64.95% Upside)
Technical Analysis
Ownership Overview
10.45% Insiders
39.03% Mutual Funds
0.61% Other Institutional Investors
40.51% Public Companies and Individual Investors